KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Inventory (2016 - 2025)

Biogen has reported Inventory over the past 17 years, most recently at $2.2 billion for Q4 2025.

  • Quarterly results put Inventory at $2.2 billion for Q4 2025, down 11.88% from a year ago — trailing twelve months through Dec 2025 was $2.2 billion (down 11.88% YoY), and the annual figure for FY2025 was $2.2 billion, down 11.88%.
  • Inventory for Q4 2025 was $2.2 billion at Biogen, down from $2.2 billion in the prior quarter.
  • Over the last five years, Inventory for BIIB hit a ceiling of $3.0 billion in Q3 2023 and a floor of $1.2 billion in Q1 2021.
  • Median Inventory over the past 5 years was $1.8 billion (2022), compared with a mean of $1.9 billion.
  • Biggest five-year swings in Inventory: skyrocketed 116.9% in 2023 and later decreased 17.21% in 2024.
  • Biogen's Inventory stood at $1.4 billion in 2021, then fell by 0.53% to $1.3 billion in 2022, then skyrocketed by 87.99% to $2.5 billion in 2023, then fell by 2.65% to $2.5 billion in 2024, then dropped by 11.88% to $2.2 billion in 2025.
  • The last three reported values for Inventory were $2.2 billion (Q4 2025), $2.2 billion (Q3 2025), and $2.3 billion (Q2 2025) per Business Quant data.